Drug Trial Radar · NCT06517758
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
Last checked: Nov 20, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
146
Planned (sponsor's estimate)
Start
Jul 31, 2024
Primary completion
Apr 30, 2027
Study completion May 27, 2032
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jul 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is a randomized, double-blind, placebo-controlled, multicenter, Phase III study, to evaluate efficacy, safety and tolerability of iptacopan in patients with AChR+ gMG who are on stable SOC treatment. Participants who meet the eligibility criteria will be randomized in a ratio of 1:1, to receive either iptacopan or matching placebo, for 6 months (180 days) while continuing on a stable SOC treatment. The randomization will be stratified based on region.
Conditions
- Generalized Myasthenia Gravis
Interventions
IptacopanDrug
Hard gelatin capsule
Matching PlaceboOther
Hard gelatin capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline to Month 6 in Myasthenia Gravis Activity of Daily Living (MG-ADL) total scoreTime frame: Baseline to Month 6
Locations
116 sites in 18 countries. Site status is shown where the registry gives one.
Honor Health Research Institute
Scottsdale, Arizona
Fullerton Neuro and Headache Ctr
Fullerton, California
California Pacific Medical Center
Sacramento, California
Augusta University Georgia
Augusta, Georgia
University of Chicago Medical Centr
Chicago, Illinois
Prairie Heart Institute
Springfield, Illinois
Mid Atlantic Epilepsy and Sleep Ctr
Bethesda, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Henry Ford Health System
Detroit, Michigan
Duke University Medical Center
Durham, North Carolina
Penn Presbyterian Medical Center
Philadelphia, Pennsylvania
Vanderbilt University Medical CenterX
Nashville, Tennessee
Nerve and Muscle Center of Texas
Houston, Texas
Novartis Investigative Site
Buenos Aires, Argentina
Novartis Investigative Site
Caba, Argentina
Novartis Investigative Site
Caba, Argentina
Novartis Investigative Site
Capital Federal, Argentina
Novartis Investigative Site
Córdoba, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
Córdoba, Córdoba Province, Argentina
Novartis Investigative Site
Rosario, Santa Fe Province, Argentina
Novartis Investigative Site
Camperdown, Sydney, Australia
Novartis Investigative Site
Bahia, Brazil
Novartis Investigative Site
São Paulo, Brazil
Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, Brazil
Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, Brazil
Novartis Investigative Site
Joinville, Santa Catarina, Brazil
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Fujian, China
Novartis Investigative Site
Jinan, China
Novartis Investigative Site
Hefei, Anhui, China
Novartis Investigative Site
Guangzhou, Guangdong, China
Novartis Investigative Site
Shenzhen, Guangdong, China
Novartis Investigative Site
Shijiazhuang, Hebei, China
Novartis Investigative Site
Changsha, Hunan, China
Novartis Investigative Site
Suzhou, Jiangsu, China
Novartis Investigative Site
Xi'an, Shaanxi, China
Novartis Investigative Site
Xianyang, Shaanxi, China
Showing 40 of 116 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.